title: Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.
abstract: Long-term immunity to measles, mumps, and rubella viruses was studied in 57 patients after allogeneic bone marrow transplantation. Among patients who were seropositive at the time of transplant, 51% had retained antibodies to measles, 42% had retained antibodies to mumps, and 76% had retained antibodies to rubella 2 y later. There was no difference in the ability to retain antibodies to these viruses between patients with and those without chronic graft-versus-host disease (GVHD). Twenty seronegative patients without active chronic GVHD or ongoing immunosuppressive treatment were vaccinated with a live attenuated trivalent vaccine against measles, mumps, and rubella. No early or late side effects were detected after the vaccinations. The percentages of patients who seroconverted after vaccination were 77%, 64%, and 75% for measles, mumps, and rubella, respectively. Vaccination of transplant recipients with a live attenuated vaccine against measles, mumps, and rubella is safe and usually effective 2 y after transplant if the patients do not have active chronic GVHD or ongoing immunosuppressive treatment at the time of vaccination.
authors.affiliation: Department of Medicine, Karolinska Institute, Huddinge Hospital, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Ljungman
authors.forename: E
authors.initials: E
authors.lastname: Fridell
authors.forename: B
authors.initials: B
authors.lastname: Lönnqvist
authors.forename: P
authors.initials: P
authors.lastname: Bolme
authors.forename: M
authors.initials: M
authors.lastname: Böttiger
authors.forename: G
authors.initials: G
authors.lastname: Gahrton
authors.forename: A
authors.initials: A
authors.lastname: Linde
authors.forename: O
authors.initials: O
authors.lastname: Ringdén
authors.forename: B
authors.initials: B
authors.lastname: Wahren
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations / Q000009:adverse effects / Q000276:immunology; D006086:Graft vs Host Disease / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy; D007223:Infant; D008457:Measles / Q000276:immunology*; D008458:Measles Vaccine / Q000009:adverse effects / Q000276:immunology*; D008459:Measles virus / Q000276:immunology; D022542:Measles-Mumps-Rubella Vaccine; D008875:Middle Aged; D009107:Mumps / Q000276:immunology*; D009108:Mumps Vaccine / Q000009:adverse effects / Q000276:immunology*; D009109:Mumps virus / Q000276:immunology; D012409:Rubella / Q000276:immunology*; D012411:Rubella Vaccine / Q000009:adverse effects / Q000276:immunology*; D012412:Rubella virus / Q000276:immunology; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D004338:Drug Combinations; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D012411:Rubella Vaccine; D014613:Vaccines, Attenuated; C040901:rubella antibodies